AIM: Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS). PATIENTS & METHODS: Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot. RESULTS: Increased tau and decreased BDNF in MS patients compared with controls was found. Total-tau has a peak in relapsing-remitting MS, the second decile of the multiple sclerosis severity score, and in the lowest expanded disability status scale and is no different than controls for secondary-progressive MS patients and the most severe cases of MS. CONCLUSION: BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS.
AIM: Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS). PATIENTS & METHODS: Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot. RESULTS: Increased tau and decreased BDNF in MS patients compared with controls was found. Total-tau has a peak in relapsing-remitting MS, the second decile of the multiple sclerosis severity score, and in the lowest expanded disability status scale and is no different than controls for secondary-progressive MS patients and the most severe cases of MS. CONCLUSION:BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS.
Entities:
Keywords:
Western blot; binary logistic regression; biomarker; brain-derived neurotrophic factor; diagnosis; expanded disability status scale; multiple sclerosis; multiple sclerosis severity score; progression; tau
Authors: E C D Gonçalves; V Lieberknecht; V V Horewicz; B D Rabelo; F A Felipetti; A L S Rodrigues; D F Martins; R C Dutra Journal: Mol Neurobiol Date: 2021-08-25 Impact factor: 5.590
Authors: Nikolay Mehterov; Danail Minchev; Maria Gevezova; Victoria Sarafian; Michael Maes Journal: Mol Neurobiol Date: 2022-06-03 Impact factor: 5.682
Authors: Johanna Andrea Gutiérrez-Vargas; John Fredy Castro-Álvarez; Jose Fernando Zapata-Berruecos; Komal Abdul-Rahim; Anibal Arteaga-Noriega Journal: Biomed Rep Date: 2022-02-18